Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kala Pharmaceuticals (NASDAQ:KALA) announced on December 17, 2021, the grant of non-statutory stock options to four new employees, totaling 13,500 shares. The options were issued as inducement awards outside the 2017 Equity Incentive Plan and have an exercise price of $1.44 per share, reflecting the stock's closing price on the grant date. Options will vest over four years, with 25% vesting after the first year and the rest in monthly installments, contingent on continued employment.
Positive
- Grant of stock options to four new employees indicates confidence in hiring talent.
- Stock options priced at the current market value may align employee incentives with shareholder interests.
Negative
- None.
Details
News Market Reaction – KALA
The recorded move for KALA in the trading session of this news was -2.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 13,500 shares of Kala Pharmaceuticals common stock to four new employees. The stock options were granted on December 15, 2021. The grants were approved by the Compensation Committee and were made as an inducement material to each employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About Kala Pharmaceuticals, Inc.
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension)
Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-810-4086
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.